CCR4 CAR-T

CCR4 CAR-T refers to a form of chimeric antigen receptor T cell therapy in which autologous T cells are genetically engineered to express a synthetic receptor (CAR) targeting the CC chemokine receptor 4 (CCR4). This therapy is primarily under investigation for T-cell lymphomas and other mature T-cell malignancies, which often overexpress CCR4. By recognizing CCR4, these modified T cells selectively kill CCR4-expressing malignant T cells. Unique challenges in this therapy include "fratricide" (CAR-T cells targeting resident CCR4+ normal T cells), but preclinical studies show selective depletion of Th2, Th17, and regulatory T cells (Treg), with sparing of Th1 and CD8+ T cells. Effectiveness has been demonstrated in preclinical models, and the therapy can induce long-term remission in animal models of human T-cell lymphoma[1][3]. The CAR construct typically includes antigen recognition domains derived from anti-CCR4 antibodies (distinct from mogamulizumab), a CD8 transmembrane domain, and intracellular signaling domains such as 4-1BB and CD3-zeta to provide activation and co-stimulation[3]. As of the latest available data, CCR4 CAR-T therapies have not received FDA approval and remain in preclinical and/or early-phase clinical development.

Other names

CCR4 CAR T cell therapyCCR-4 CAR T cell therapyCCR 4 CAR T cell therapyanti-CCR4 CAR-Tanti-CCR-4 CAR-Tanti-CCR 4 CAR-TCCR4-targeted CAR-TCCR-4-targeted CAR-TCCR 4-targeted CAR-T